How to buy Eliem Therapeutics stock (Eliem Therapeutics)

Eliem Therapeutics is a biotechnology business based in the US. Eliem Therapeutics shares (ELYM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.09 – the same closing value as a week prior. Eliem Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Eliem Therapeutics stock

Buy Eliem Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Eliem Therapeutics stock price (NASDAQ: ELYM)

Use our graph to track the performance of ELYM stocks over time.

Eliem Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-22.

Latest market close	$3.09
52-week range	$2.52 - $11.55
50-day moving average more info button	$6.46
200-day moving average more info button	$5.57
Wall St. target price	$4.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.22

Is it a good time to buy Eliem Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eliem Therapeutics price performance over time

Historical closes compared with the close of $3.09 from 2024-12-04

1 week (2024-12-17)	N/A
1 month (2024-11-27)	-4.04%
3 months (2024-09-27)	-37.95%
6 months (2024-06-28)	-56.54%

1 year (2023-12-28)	13.19%
2 years (2022-12-28)	7.67%
3 years (2021-12-28)	12.42
5 years (2019-12-24)	N/A

Eliem Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-24.54%
Return on equity TTM	-38.35%
Profit margin	0%
Book value	$3.33
Market Capitalization more info button	$342.7 million

TTM: trailing 12 months

Eliem Therapeutics share dividends

We're not expecting Eliem Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Sanofi ADR (SNY.US) (4.27% forward annual dividend yield)

Eliem Therapeutics share price volatility

Over the last 12 months, Eliem Therapeutics's shares have ranged in value from as little as $2.52 up to $11.55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eliem Therapeutics's is -0.382. This would suggest that Eliem Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Eliem Therapeutics has bucked the trend.

To put Eliem Therapeutics's beta into context you can compare it against those of similar companies.

• Sanofi ADR (SNY.US): 0.445
• Atea Pharmaceuticals Inc (AVIR.US): 0.17
• Biogen (BIIB.US): -0.061

Eliem Therapeutics overview

Eliem Therapeutics, Inc. , a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware. .

Frequently asked questions

null
What percentage of Eliem Therapeutics is owned by insiders or institutions?
Currently 10.382% of Eliem Therapeutics shares are held by insiders and 77.671% by institutions. How many people work for Eliem Therapeutics?
Latest data suggests 9 work at Eliem Therapeutics. When does the fiscal year end for Eliem Therapeutics?
Eliem Therapeutics's fiscal year ends in December. Where is Eliem Therapeutics based?
Eliem Therapeutics's address is: PMB #117, 2801 Centerville Road, Wilmington, DE, United States, 19808-1609 What is Eliem Therapeutics's ISIN number?
Eliem Therapeutics's international securities identification number is: US28658R1068